4D Molecular Therapeutics, Inc. General and Administrative Expense
4D Molecular Therapeutics, Inc. (FDMT) reported General and Administrative Expense of $12.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. general and administrative expense for the quarter ending 2026-06-30 was $12.52M, a 8.72% increase year-over-year.
- 4D Molecular Therapeutics, Inc. general and administrative expense for the quarter ending 2026-03-31 was $11.69M, a 9.66% decline year-over-year.
- 4D Molecular Therapeutics, Inc. general and administrative expense for the quarter ending 2025-12-31 was $12.77M, a 2.03% decline year-over-year.
- 4D Molecular Therapeutics, Inc. general and administrative expense for the quarter ending 2025-09-30 was $11.84M, a 6.43% decline year-over-year.
- 4D Molecular Therapeutics, Inc. general and administrative expense for fiscal 2025 was $49.06M, a 5.33% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. general and administrative expense for fiscal 2024 was $46.58M, a 27.63% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. general and administrative expense for fiscal 2023 was $36.49M, a 10.90% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. general and administrative expense for fiscal 2022 was $32.91M, a 17.48% increase from fiscal 2021.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 6 month | General and Administrative Expense 9 month | General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.52M 10-Q · filed 2026-08-13 | $24.21M 10-Q · filed 2026-08-13 | $36.98M derived: sum of 3 quarters · filed 2026-08-13 | $48.81M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $11.69M 10-Q · filed 2026-05-07 | $24.45M derived: sum of 2 quarters · filed 2026-05-07 | $36.29M derived: sum of 3 quarters · filed 2026-05-07 | $47.81M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $12.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $24.60M derived: sum of 2 quarters · filed 2026-03-18 | $36.12M derived: sum of 3 quarters · filed 2026-08-13 | $49.06M 10-K · filed 2026-03-18 |
| 2025-09-30 | $11.84M 10-Q · filed 2025-11-10 | $23.36M derived: sum of 2 quarters · filed 2026-08-13 | $36.29M 10-Q · filed 2025-11-10 | $49.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $11.52M 10-Q · filed 2026-08-13 | $24.46M 10-Q · filed 2026-08-13 | $37.49M derived: sum of 3 quarters · filed 2026-08-13 | $50.14M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $12.94M 10-Q · filed 2026-05-07 | $25.97M derived: sum of 2 quarters · filed 2026-05-07 | $38.62M derived: sum of 3 quarters · filed 2026-05-07 | $49.22M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $13.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $25.68M derived: sum of 2 quarters · filed 2026-03-18 | $36.28M derived: sum of 3 quarters · filed 2026-03-18 | $46.58M 10-K · filed 2026-03-18 |
| 2024-09-30 | $12.65M 10-Q · filed 2025-11-10 | $23.25M derived: sum of 2 quarters · filed 2025-11-10 | $33.55M 10-Q · filed 2025-11-10 | $44.15M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $10.60M 10-Q · filed 2025-08-11 | $20.90M 10-Q · filed 2025-08-11 | $31.50M derived: sum of 3 quarters · filed 2025-08-11 | $40.61M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $10.29M 10-Q · filed 2025-05-08 | $20.90M derived: sum of 2 quarters · filed 2025-05-08 | $30.01M derived: sum of 3 quarters · filed 2025-05-08 | $38.80M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $10.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $19.72M derived: sum of 2 quarters · filed 2025-02-28 | $28.51M derived: sum of 3 quarters · filed 2025-02-28 | $36.49M 10-K · filed 2025-02-28 |
| 2023-09-30 | $9.11M 10-Q · filed 2024-11-13 | $17.90M derived: sum of 2 quarters · filed 2024-11-13 | $25.89M 10-Q · filed 2024-11-13 | $34.36M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $8.79M 10-Q · filed 2024-08-08 | $16.78M 10-Q · filed 2024-08-08 | $25.25M derived: sum of 3 quarters · filed 2024-08-08 | $33.30M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $7.99M 10-Q · filed 2024-05-09 | $16.46M derived: sum of 2 quarters · filed 2024-05-09 | $24.51M derived: sum of 3 quarters · filed 2024-05-09 | $32.68M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $16.52M derived: sum of 2 quarters · filed 2024-02-29 | $24.69M derived: sum of 3 quarters · filed 2024-02-29 | $32.91M 10-K · filed 2024-02-29 |
| 2022-09-30 | $8.05M 10-Q · filed 2023-11-09 | $16.22M derived: sum of 2 quarters · filed 2023-11-09 | $24.44M 10-Q · filed 2023-11-09 | $31.78M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $8.17M 10-Q · filed 2023-08-09 | $16.38M 10-Q · filed 2023-08-09 | $23.72M derived: sum of 3 quarters · filed 2023-08-09 | $31.91M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $8.23M 10-Q · filed 2023-05-11 | $15.56M derived: sum of 2 quarters · filed 2023-05-11 | $23.75M derived: sum of 3 quarters · filed 2023-05-11 | $30.70M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $15.52M derived: sum of 2 quarters · filed 2023-03-15 | $22.47M derived: sum of 3 quarters · filed 2023-03-15 | $28.01M 10-K · filed 2023-03-15 |
| 2021-09-30 | $8.19M 10-Q · filed 2022-11-08 | $15.14M derived: sum of 2 quarters · filed 2022-11-08 | $20.68M 10-Q · filed 2022-11-08 | $27.52M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $6.95M 10-Q · filed 2022-08-11 | $12.50M 10-Q · filed 2022-08-11 | $19.34M derived: sum of 3 quarters · filed 2022-08-11 | $23.02M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $5.54M 10-Q · filed 2022-05-12 | $12.38M derived: sum of 2 quarters · filed 2022-05-12 | $16.07M derived: sum of 3 quarters · filed 2022-05-12 | $19.13M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $6.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $10.52M derived: sum of 2 quarters · filed 2022-03-28 | $13.58M derived: sum of 3 quarters · filed 2022-03-28 | $17.24M 10-K · filed 2022-03-28 |
| 2020-09-30 | $3.68M 10-Q · filed 2021-11-10 | $6.74M derived: sum of 2 quarters · filed 2021-11-10 | $10.40M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.06M 10-Q · filed 2021-08-12 | $6.72M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $3.65M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $13.89M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |